Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418). This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback